Want to see CH:EVE full AI Analyst Report?
Top Page
Evolva Holding
(EVE)
Select Model
Select Model
Rating:50Neutral
Price Target:
CHF2.50
▲(7.76% Upside)
Action:Reiterated
Date:10/13/26
The score is held down primarily by weak financial performance (zero recent revenue and persistent negative operating/free cash flow), with only partial support from a low-debt balance sheet. Technicals are a clear positive (price above key moving averages with positive MACD), but valuation is constrained by negative earnings and no dividend support.
Positive Factors
Low Financial Leverage
No debt from 2023–2025 limits interest-bearing obligations and reduces balance-sheet strain. This gives Evolva greater financial flexibility to preserve resources, pursue its ingredient and biotechnology activities, or withstand operating volatility without added lender pressure.
Negative Factors
Zero Recent Revenue
Revenue dropping to zero in both 2024 and 2025 indicates that Evolva currently lacks a durable operating revenue base. Without recurring sales, the company has limited evidence of commercial scale, making future profitability and self-funded growth dependent on rebuilding meaningful business activity.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
No debt from 2023–2025 limits interest-bearing obligations and reduces balance-sheet strain. This gives Evolva greater financial flexibility to preserve resources, pursue its ingredient and biotechnology activities, or withstand operating volatility without added lender pressure.
Read all positive factors
Evolva Holding (EVE) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF16.45M
Dividend YieldN/A
Average Volume (3M)31.14K
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue GrowthN/A
EPS Growth-39.83%
CountryCH
Employees49
SectorFinancial
Sector Strength70
IndustryShell Companies
Share Statistics
EPS (TTM)-0.13
Shares Outstanding7,230,626
10 Day Avg. Volume46,212
30 Day Avg. Volume31,136
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.5
Revenue Forecast (FY)CHF60.90M
Evolva Holding Business Overview & Revenue Model
Company Description
EvoNext Holdings SA is dedicated to the exploration, creation, and distribution of pioneering ingredients across the nutritional, health, and wellness domains. Founded in 2004, the company's inception is attributed to Alexandra Santana Sørensen, S...
Evolva Holding Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 9.44M | 15.54M | 9.88M |
| Gross Profit | 0.00 | 0.00 | 0.00 | -4.83M | -8.89M | -9.31M |
| EBITDA | -775.00K | -652.10K | 3.96M | -98.36M | -34.52M | -31.82M |
| Net Income | -926.70K | -652.70K | 1.04M | -105.23M | -43.37M | -41.27M |
Balance Sheet | ||||||
| Total Assets | 5.57M | 6.76M | 7.54M | 9.83M | 131.01M | 156.17M |
| Cash, Cash Equivalents and Short-Term Investments | 4.22M | 5.61M | 6.75M | 5.84M | 5.14M | 11.00M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 15.06M | 10.84M |
| Total Liabilities | 264.10K | 812.70K | 945.30K | 4.28M | 24.77M | 24.40M |
| Stockholders Equity | 5.31M | 5.94M | 6.60M | 5.55M | 106.24M | 131.77M |
Cash Flow | ||||||
| Free Cash Flow | -2.10M | 0.00 | -2.44M | -9.72M | -21.13M | -33.57M |
| Operating Cash Flow | -2.10M | -1.14M | -2.44M | -9.25M | -18.88M | -29.79M |
| Investing Cash Flow | 0.00 | 0.00 | 3.52M | 15.95M | -1.76M | -4.64M |
| Financing Cash Flow | 0.00 | 0.00 | -163.10K | -5.97M | 14.77M | 25.72M |
Evolva Holding Technical Analysis
Positive
2.32
Price Trends
2.27
Positive
2.18
Positive
1.58
Positive
Market Momentum
0.04
Positive
49.21
Neutral
28.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:EVE, the sentiment is Positive. The current price of 2.32 is above the 20-day moving average (MA) of 2.30, above the 50-day MA of 2.27, and above the 200-day MA of 1.58, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 49.21 is Neutral, neither overbought nor oversold. The STOCH value of 28.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:EVE.
Evolva Holding Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | CHF6.21B | 41.63 | 10.27% | 1.09% | 4.51% | 11.05% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
67 Neutral | CHF43.26B | -412.21 | ― | 0.79% | -10.77% | -114.77% | |
63 Neutral | CHF834.89M | 116.02 | 10.24% | ― | 40.91% | ― | |
51 Neutral | CHF127.99M | -2.33 | -67.67% | ― | -100.00% | 24.46% | |
50 Neutral | CHF16.45M | -17.74 | -16.47% | ― | ― | -39.83% |
* Financial Sector Average
CH:EVE
Evolva Holding
2.28
1.34
142.55%
CH:MOLN
Molecular Partners AG
3.17
0.32
11.23%
CH:LONN
Lonza Group Ltd
634.80
62.20
10.86%
CH:BANB
Bachem Holding AG
82.85
25.09
43.45%
CH:KURN
Kuros Biosciences
21.00
-8.18
-28.03%
CH:XLS
Xlife Sciences Ltd.
8.70
-11.30
-56.50%
Evolva Holding Corporate Events
Ascend to Go Public via EvoNext Merger in CHF 500m Sports Tech Deal
Oct 12, 2026
EvoNext Holdings SA and Ascend Sport Technology AG have agreed to merge in a statutory transaction that will take Ascend public via EvoNext’s existing listing on SIX Swiss Exchange, creating a listed Swiss sports technology company with glob...
EvoNext Posts Modest Loss as Talks Advance on Reverse Merger with Ascend Sport Technology
Sep 30, 2026
EvoNext Holdings SA reported liquidity of CHF 5.5 million and equity of CHF 5.3 million as of 30 June 2026, with a net loss of CHF 0.6 million driven mainly by one-off transaction and search-related costs. The company’s half-year figures hig...
EvoNext in advanced talks on reverse merger with AI sports tech firm Ascend
Aug 17, 2026
EvoNext Holdings SA has confirmed it is in advanced talks with Ascend Sport Technology AG over a reverse merger that would bring the profitable, AI-driven Swiss sports technology firm to the SIX Swiss Exchange. The contemplated deal envisages valu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.